This Biotech Could be the Next Moderna, Pfizer, or even BioNTech

Flying Well Under the Radar, This Biotech Firm May Hold All the Cards in a Potential $58.4 Billion Vaccine Market

While vaccine developers like Moderna, Pfizer, and BioNTech expect to book billions in revenues this year, a $260 million biotech firm could soon get caught up in the boom.

Not only did the company just announce its vaccine is effective in non-rodent models, it kicked the immune response into high gear.

It was even effective against all tested variants including the Delta strain.

No wonder the stock was up about 366% since May 2021.

Better, if further trials show success, it could open the door to an immediate $1 billion to $2 billion in revenues from pharmaceutical companies lining up for the treatment. Can you imagine what would happen to a tiny $260 million stock if that happens?

Click here to learn more about this opportunity.

Regards,
Biotech Trends Report

This is a PAID ADVERTISEMENT provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click here.

DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Schaeffer's Investment Research, Inc. "Schaeffer's" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this advertisement. Schaeffer's has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.

Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the websites of the U.S. Securities and Exchange Commission (the "SEC") and the Financial Industry Regulatory Authority (the "FINRA"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud on the SEC website, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.


Schaeffer's Investment Research
5151 Pfeiffer Road, Suite 250
Cincinnati, Ohio 45242

No comments:

Post a Comment